Objective: To investigate the factors to predict Gleason score upgrading (GSU) of patients with prostate cancer who were evaluated by using the International Society for Urological Pathology (ISUP) 2014 Gleason grading system.
Introduction
Prostate cancer, one of the common cancer types, is one of the frequent reasons for cancer deaths. [1] The Gleason score is used for the histologic grading of prostate cancer, and it is one of the important markers in making treatment decisions. [2] The Gleason grading system was first defined in 1966 and updated in subsequent years, its last update being in 2014 by the International Society for Urological Pathology (ISUP). [3, 4] There is a compliance problem between Gleason scores estimated for transrectal prostate biopsy and radical prostatectomy specimens up to 50% in the literature. [5, 6] Having such different results for a parameter that is quite influential in therapeutic decision making creates a need for other markers in choosing the ideal treatment. Especially, it is difficult and risky to decide active surveillance.
We aimed to investigate factors that affected Gleason score upgrading (GSU) of the patients with prostate cancer who were evalu- 
Results
Of the 265 patients who could be evaluated and followed up regularly, median age of the patients was 63.1 years (range, 44-76 years), median PSA (13 ng/mL: range, 2-125 ng/mL), BMI (27.2 kg/m
2 ) values and follow-up time (46.08 months: range, 12-110 months)
were as indicated (Table 1) . Gleason score upgrades were observed in 110 (41.5%) patients. A total of 22 patients had extraprostatic spread, and 13 patients had seminal vesicle invasion. Higher ISUP grades were estimated for radical prostatectomy specimens in respective number of patients in Groups 1 (n=97), 2 (n=72), 3 (n=33), 4 (n=29), and 5 (n=34). During the follow-up period 65 Table 2) .
Turan The five-year biochemical recurrence-free survival rate was 86% in the non-GSU group and 55% in the GSU group. There was a significant difference in the biochemical recurrence-free survival rates based on the Kaplan-Meier survival analysis (logrank p<0.001) (Figure 1 ).
Discussion
The Gleason score is a highly effective parameter in making therapeutic decisions for prostate cancer. Identifying the Gleason score correctly helps physicians to decide on various treatment options such as active monitoring, radical prostatectomy, radiotherapy or adjuvant/salvage androgen deprivation therapy (ADT) with curative treatment accurately. Owing to the WHO/ISUP 2014 decision, patients who scored low can later on have higher scores. Additionally, grade grouping provided a more convenient use. In this study, we reevaluated the Gleason scores and discovered upgrades in 41% of the patients. Similar to previous studies, advanced age was found to have a correlation with increased upgrade risk in the multivariate analysis. [6] [7] [8] [9] Decisions should be made more carefully for advanced-age groups due to their comorbidities, and despite popular belief, these patients have a higher risk for an aggressive disease. Moreover, patients undergoing radiotherapy (RT) and also active surveillance groups whose final Gleason scores cannot be found should be watched closely in order to prevent emergence of poor oncologic results.
Accurate evaluation of biopsy Gleason scores matters a great deal for the nomograms that aim to determine patients' pathologic stage in clinical practice. [10] Factors such as PSA, PSA density, prostate volume, BMI, CAPRA score, positive core percentage, low serum testosterone level, and prolonged time intervals between biopsy and surgery were found to be correlated with upgrades. [11] [12] [13] [14] [15] [16] In our study, most of these factors were found to be effective in the univariate analysis but insignificant in the multivariate analysis. The reasoning behind this could be the fact that we used the new grading system.
In accordance with the literature, a relationship was detected between GSU and biochemical recurrence in the present study (p=0.001). [17, 18] In a study by Santok et al. [19] , the biochemical recurrence-free survival, cancer-specific survival, and overall survival rates were comparatively lower in patients who underwent robot-assisted radical prostatectomy (RARP) and had Gleason score upgrading (p≤0.001, p=0.003, and p=0.01). In order to demonstrate the relationship between GSU and the disease progression, the long-term monitoring was needed in our study.
Standard transrectal prostate biopsies and randomized sampling could make it difficult to determine the Gleason score accurately for multifocal prostate cancer. Magnetic resonance imaging (MRI) in prostate cancer allows the opportunity for disease staging and targeted biopsy. [20] [21] [22] Prostate biopsies performed with the aid of fusion-guided MRI/ultrasonography (US), detected 14.3% of prostate cancers that could not be detected using standard 12-core prostate biopsy. Diagnosis by using fusion biopsy, 86.7% of patients had clinically significant prostate cancer. [23] Lai et al. [24] reported that the results from MRItargeted biopsies and findings from MRI could predict upgrade risk for patients with prostate cancer in the active surveillance group. Using MRI fusion biopsy, 26% of upgraded cases could be detected. The assumption that it is only possible to perform targeted biopsies from index lesions accurately and safely in special experienced centers based on the still-developing Prostate Imaging Reporting and Data System (PIRADS) classification precludes widespread use of MRI in the short term.
Genomic tests can provide valuable information on risks for radical prostatectomy performed after biochemical recurrence, metastasis, cancer-specific mortality or postoperative course of prostate cancer after RT. [25] [26] [27] [28] Although genomic tests are included in current guidelines, there is still a need for a solution towards financial issues concerning its widespread clinical use. [29] Additionally, it was reported that the number of cancer-propagating cells found in prostate cancer (CPCs) correlated with GSU. [30] In order to provide patients with a safe and effective treatment plan, it would be ideal to acquire all final histopathological information. However, since the common choices in the current management of prostate cancer include options such as active surveillance and RT, current data will not be enough to overcome the problem of GSU. A model that combines MRI The limitations of the present study included the need for long-term monitorization to evaluate cancer-specific survival and metastasis. The study was designed to be a retrospective trial and, the patients whose MRI information was not available were not included in the study. There is a gap in the field for prospective studies concerning MRI findings and genomic profiles.
Advanced age can be accepted as a predictive factor for GSU and, GSU risk should be taken into consideration in making therapeutic decisions for older patients with prostate cancer, and precautions should be taken to prevent development of aggressive disease.
